Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Novavax, Inc is a biotechnology business based in the US. Novavax shares (NVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Novavax employs 359 staff and has a trailing 12-month revenue of around USD$50.2 million.
Since the stock market crash in March caused by coronavirus, Novavax's share price has had significant positive movement.
Its last market close was USD$108.36, which is 92.88% up on its pre-crash value of USD$7.72 and 1,630.99% up on the lowest point reached during the March crash when the shares fell as low as USD$6.26.
If you had bought USD$1,000 worth of Novavax shares at the start of February 2020, those shares would have been worth USD$1,580.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$15,911.58.
|Latest market close||USD$108.36|
|52-week range||USD$3.54 - USD$189.4|
|50-day moving average||USD$126.0882|
|200-day moving average||USD$68.7968|
|Wall St. target price||USD$227.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-8.597|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-14)||2.42%|
|1 month (2020-08-21)||-21.26%|
|3 months (2020-06-19)||67.35%|
|6 months (2020-03-20)||946.96%|
|1 year (2019-09-20)||1,554.35%|
|2 years (2018-09-21)||6,672.50%|
|3 years (2017-09-21)||9,241.38%|
|5 years (2015-09-21)||993.44%|
|Revenue TTM||USD$50.2 million|
|Gross profit TTM||USD$-95,180,000|
|Return on assets TTM||-10.32%|
|Return on equity TTM||-93.79%|
|Market capitalisation||USD$6.6 billion|
TTM: trailing 12 months
There are currently 9.5 million Novavax shares held short by investors – that's known as Novavax's "short interest". This figure is 17.1% up from 8.1 million last month.
There are a few different ways that this level of interest in shorting Novavax shares can be evaluated.
Novavax's "short interest ratio" (SIR) is the quantity of Novavax shares currently shorted divided by the average quantity of Novavax shares traded daily (recently around 9.7 million). Novavax's SIR currently stands at 0.98. In other words for every 100,000 Novavax shares traded daily on the market, roughly 980 shares are currently held short.
However Novavax's short interest can also be evaluated against the total number of Novavax shares, or, against the total number of tradable Novavax shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novavax's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Novavax shares in existence, roughly 140 shares are currently held short) or 0.1389% of the tradable shares (for every 100,000 tradable Novavax shares, roughly 139 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novavax.
Find out more about how you can short Novavax stock.
We're not expecting Novavax to pay a dividend over the next 12 months.
Novavax's shares were split on a 1:20 basis on 10 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.
Over the last 12 months, Novavax's shares have ranged in value from as little as $3.54 up to $189.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.5028. This would suggest that Novavax's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.